文献速递妇科

胰高血糖素样肽-1受体激动剂用于体重管理:面向妇科肿瘤学家的综述

Glucagon-like peptide-1 (GLP-1) receptor agonists for weight management: A review for the gynecologic oncologist.
PubMed 文献 · Gynecol Oncol · 2024-08-07

本文综述了胰高血糖素样肽-1受体激动剂(GLP-1RA)在体重管理中的作用,及其对妇科恶性肿瘤患者的潜在影响。GLP-1RA联合生活方式干预可使超重或肥胖成人显著减重,并改善高血糖、胰岛素敏感性、血压、心脏代谢参数及肾功能,可能降低多种肥胖相关癌症风险;药物毒性主要为胃肠道反应,积极管理可防止停药。肥胖与恶性肿瘤发病率增加及生存期缩短相关,仍需更多研究评估GLP-1RA在肿瘤学中的前瞻性应用。

要点

  • GLP-1RA联合生活方式干预可使超重或肥胖成人显著减重,并改善心脏代谢参数。
  • 药物相关毒性主要为胃肠道反应,积极管理可防止停药。
  • 肥胖与恶性肿瘤发病率增加及生存期缩短相关,GLP-1RA可能降低多种肥胖相关癌症风险。

核心结论

  • GLP-1RA可显著减重并改善代谢参数,可能降低多种肥胖相关癌症风险,但仍需更多研究评估其在肿瘤学中的前瞻性应用。

研究设计与样本

  • 本文为综述,检索范围原文未报告。

主要发现

  • GLP-1RA联合生活方式干预可使超重或肥胖成人显著减重。
  • GLP-1RA可改善高血糖、增强胰岛素敏感性、调节血压、改善心脏代谢参数、减轻肾功能障碍,并可能降低多种肥胖相关癌症风险。
  • 药物相关毒性主要为胃肠道反应,积极管理可防止停药。
  • 肥胖与恶性肿瘤发病率增加及生存期缩短相关。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文指出仍需更多研究评估GLP-1RA调节脂肪细胞内分泌功能、调控肥胖相关慢性炎症状态及在肿瘤学中的前瞻性应用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The use of glucagon-like peptide-1 receptor agonists (GLP-1RA) has experienced rapid growth amidst the obesity epidemic in the United States. While originally developed for glucose control in Type 2 Diabetes Mellitus, the scope of these agents now extends to encompass weight loss and cardiovascular risk reduction. GLP-1RAs have the potential to induce significant weight loss, in combination with lifestyle modifications, among adults who are overweight or obese. Furthermore, these agents demonstrate efficacy in ameliorating hyperglycemia, enhancing insulin sensitivity, regulating blood pressure, improving cardiometabolic parameters, mitigating kidney dysfunction, and potentially reducing the risk of several obesity-related cancers. Drug-related toxicity is primarily gastrointestinal and active management can prevent drug discontinuation. Obesity is associated both with an increased incidence of malignancy but also with decreased survival. More research is needed to evaluate the potential use of GLP-1RA to modify the endocrine function of adipocytes, regulate the chronic inflammatory state associated with obesity, and prospective applications in oncology. These agents can impact patients with gynecologic malignancies both through their direct mechanism of action as well as potential drug toxicity.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Riedinger CJ, Sakach J, Maples JM, et al. Glucagon-like peptide-1 (GLP-1) receptor agonists for weight management: A review for the gynecologic oncologist. Gynecol Oncol. 2024. PMID: 39116625. doi:10.1016/j.ygyno.2024.07.008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。